Skip to content
Open access

11-Oxygenated Androgens in Pcos: Impact of Pcos Phenotypes and First-Line Interventions.

Aug 2026 · Journal of Clinical Endocrinology and Metabolism · 0 citations
Medicine

TL;DR

11-oxygenated androgens are elevated in PMOS in a phenotype-specific manner and are strongly suppressed by OCPs, with modest response to metformin and no short-term effect from LSM, supporting their utility in phenotyping and treatment monitoring.

Abstract

Context

Androgen excess in polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is classically attributed to ovarian steroids, yet adrenal-derived 11-oxygenated androgens are potent contributors whose regulation and treatment responsiveness in PMOS remains poorly characterized.

Objective

To quantify classic and 11-oxygenated androgens across PMOS phenotypes versus controls and to evaluate their responses to oral contraceptive pills (OCPs), metformin, or lifestyle modification (LSM).

Design

Secondary analysis of residual serum samples from three trials: OWL-PCOS (16-week OCP vs LSM), COMET-PCOS (24-week OCP vs metformin), and AMIGOS (controls).

Setting

Two academic medical centers. PATIENTS OR OTHER

Participants

276 with Rotterdam-defined PMOS and 97 controls. INTERVENTION(S) Low dose OCPs (4-6 months), metformin (2000mg/day for 6 months), or LSM (4 months). MAIN OUTCOME MEASURE(S) Serum concentrations of 11β-hydroxytestosterone (11-OHT), 11-ketotestosterone (11-KT), 11-ketoandrostenedione (11-KA4), and 11β-hydroxyandrostenedione (11-OHA4) measured by LC-MS/MS, and total testosterone (TT), at baseline and end of study.

Results

Adjusting for age and BMI, women with PCOS/PMOS had higher median 11-OHT (11.0 vs 7.8 ng/dL; P = 0.01) and 11-KT (31.9 vs 25.6 ng/dL; P = 0.03) than controls. Elevations were phenotype-specific: biochemical hyperandrogenism showed broad increases, whereas clinical hyperandrogenism with normal TT found no significant differences compared to controls. OCPs suppressed 11-KT, 11-KA4, and 11-OHT (all P < 0.001), comparable to TT reductions. Metformin produced modest reductions in 11-OHT and 11-KT (P < 0.05), while LSM had no effect. Changes were independent of BMI, glycemia, and HOMA-IR.

Conclusions

11-oxygenated androgens are elevated in PMOS in a phenotype-specific manner and are strongly suppressed by OCPs, with modest response to metformin and no short-term effect from LSM, supporting their utility in phenotyping and treatment monitoring.

Read PDF

Similar papers

Review Open access Aug 2026

INOSITOLS AS A MULTIDIMENSIONAL THERAPEUTIC APPROACH TO PCOS/PMOS: EFFECTS ON METABOLIC, HORMONAL, AND REPRODUCTIVE OUTCOMES

Background Polycystic ovary syndrome (PCOS), recently renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), is one of the most common endocrine disorders affecting women of reproductive age, characterized by metabolic, hormonal, and reproductive disturbances. Current therapies mainly address symptoms and may be asso...

Izabela Staszczyk, Magdalena Warchoł, Roksana Hashemi et al. · 0 citations
Open access Oct 2026

Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.

BACKGROUND Polycystic ovary syndrome (PCOS), now polyendocrine metabolic ovarian syndrome (PMOS), is associated with reproductive and cardiometabolic complications. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists (RAs) improve obesity-related outcomes, but their impa...

A. Henney, Phoebe J. Holmes, David R. Riley et al. · 0 citations
Open access Sep 2026

Hyperandrogenism in polyendocrine metabolic ovarian syndrome is associated with increase of urinary inositol

Hyperandrogenemia, insulin resistance (IR), and metabolic disorders are cardinal features of polycystic ovary syndrome, also referred to here as Polyendocrine Metabolic Ovarian Syndrome (PMOS). Inositol supplementation can restore ovulation in women with PCOS, but the relationship between inositol and the clinica...

Wen-Hui Zhang, Yu-Long Zhang, Meng-Ting Chen et al. · 0 citations
Open access Sep 2026

The Relevance of Follicle Number and Androgens in Metabolic Alterations in Polycystic Ovary Syndrome: A Cross-Sectional Study

Background/Objectives: Polycystic Ovary Syndrome (PCOS) is characterized by reproductive and metabolic disturbances, including insulin resistance and altered ovarian morphology. The clinical manifestations of PCOS include metabolic, reproductive, and psychological issues that negatively affect quality of life, making P...

N. Cera, Joana Pinto, M. Maccarone et al. · 0 citations
Review Open access Sep 2026

Progesterone Resistance in PCOS/PMOS: Molecular Insights and Therapeutic Perspectives

Background: Polycystic ovary syndrome (PCOS), recently renamed as Polycystic Ovary Morphology and Metabolic Syndrome (PMOS), is a leading cause of female infertility. Despite successful ovulation induction treatment, many patients still fail to achieve pregnancy. This discrepancy points to impaired endometrial receptiv...

E. Golubenko, M. Poznyak, Sergey A. Timofeev et al. · 0 citations
Open access Sep 2026

Phenotype-Specific Differences in Insulin Resistance and Androgenic Profiles in Polycystic Ovary Syndrome: A Prospective Observational Study

Background and Objectives: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine and metabolic disorder characterized by distinct phenotypic presentations. This study aimed to compare androgenic and metabolic characteristics across Rotterdam-defined PCOS phenotypes, with particular emphasis on insulin resistanc...

Karolin Ohanoglu Cetinel, Ahmet Cinar, Can Tercan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.